SINGAPORE, Nov. 08, 2018 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today reported financial results for the quarter ended 30 September 2018 and provided an update on its clinical activities.
Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: “We made further progress across our clinical development programs in the third quarter with the completion of enrolment in the phase 2 part of our gastric cancer study for varlitinib, our pan-HER inhibitor, and the dosing of our first subject in a phase 1 study for ASLAN004, our IL-4/IL-13 receptor antibody. In addition, we were pleased that the US FDA granted ASLAN003 Orphan Drug Designation for the potential treatment of AML and we continued our outreach to the scientific community with a number of poster presentations at key medical meetings. We also recently took the step of strengthening our board with the addition of Robert E. Hoffman as a director of the company. Looking ahead, we have a number of potentially value-creating milestones in the near term, including readouts from our AML, biliary tract and gastric cancer programs.”
Third quarter 2018 and recent business highlights
- Completed recruitment of 52 patients for the phase 2 part of global phase 2/3 study investigating varlitinib as first line therapy in HER1/HER2 co-expressing advanced or metastatic gastric cancer patients.
- Presented new data on varlitinib showing promising results in heavily pre-treated biliary tract cancer (BTC) and colorectal cancer patients, and a poster on ASLAN003 at the 2018 European Society for Medical Oncology (ESMO) Congress in Munich, Germany.
- Presented two posters on varlitinib at Chinese Society of Clinical Oncology Annual Meeting.
- Provided update on timelines for single-arm trial of varlitinib in BTC in China.
- Granted US Orphan Drug Designation (ODD) by the US FDA for ASLAN003 as a treatment for acute myeloid leukaemia (AML).
- Dosed the first subject in a phase 1 study investigating ASLAN004 as a therapeutic antibody for atopic dermatitis.
- Appointed Robert E. Hoffman, an experienced pharmaceutical industry leader, as an Independent Non-Executive Director.
Anticipated upcoming milestones
- Presentations of preliminary phase 2a results in AML showing early signs of activity and preclinical data for ASLAN003 at the American Society of Hematology (ASH) Annual Meeting on December 2 and 3, 2018.
- Topline data from pivotal global phase 2 study on varlitinib in gastric cancer in fourth quarter of 2018.
- Interim phase 1b data on varlitinib as first line treatment for biliary tract cancer in fourth quarter of 2018.
- Complete patient enrolment in global pivotal trial (TREETOPP) with varlitinib as second line treatment for biliary tract cancer in early 2019.
- Topline data from TREETOPP in 2019.
Third quarter 2018 financial highlights
- Cash used in operations for the quarter ended 30 September 2018 was US$9.9 million compared to US$8.9 million in the same period in 2017.
- Research and development expense was US$8.7 million and general and administrative expense was US$2.7 million for the third quarter of 2018, compared to US$5.6 million and US$2.2 million respectively in the same period in 2017.
- Net loss for the third quarter of 2018 was US$11.2 million compared to a net loss of US$8.0 million for the third quarter of 2017.
- Cash, cash equivalents and short-term investments totaled US$34.8 million as of 30 September 2018 compared to US$50.6 million as of 31 December 2017.
| ASLAN Pharmaceuticals Limited | ||||||||
| Consolidated Balance Sheet1 | ||||||||
| (in US dollars, unaudited) | ||||||||
| December 31, 2017 |
September 30, 2018 |
|||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash and cash equivalents | $ | 50,573,211 | $ | 34,800,415 | ||||
| Prepayments | 71,946 | 138,587 | ||||||
| NON-CURRENT ASSETS | ||||||||
| Financial assets at fair value through other comprehensive income | – | 187,244 | ||||||
| Property, plant and equipment | 443,566 | 336,526 | ||||||
| Intangible assets | 84,052 | 23,082,221 | ||||||
| Refundable deposits | 160,947 | 177,225 | ||||||
| Total non-current assets | 688,565 | 23,783,216 | ||||||
| TOTAL ASSETS | $ | 51,333,722 | $ | 58,722,218 | ||||
| EQUITY AND LIABILITIES | ||||||||
| CURRENT LIABILITIES | ||||||||
| Trade payables | $ | 3,898,291 | $ | 3,536,989 | ||||
| Other payables | 2,080,544 | 3,190,335 | ||||||
| Total current liabilities | 5,978,835 | 6,727,324 | ||||||
| NON-CURRENT LIABILITIES | ||||||||
| Long-term borrowings | 9,679,451 | 9,791,037 | ||||||
| Other non-current liabilities | 162,000 | 425,000 | ||||||
| Total non-current liabilities | 9,841,451 | 10,216,037 | ||||||
| Total liabilities | 15,820,286 | 16,943,361 | ||||||
| EQUITY | ||||||||
| Ordinary shares | 41,514,016 | 51,627,219 | ||||||
| Capital surplus | 84,282,681 | 111,428,656 | ||||||
| Accumulated deficits | (90,283,261 | ) | (121,277,018 | ) | ||||
| Total equity | 35,513,436 | 41,778,857 | ||||||
| TOTAL EQUITY AND LIABILITIES | $ | 51,333,722 | $ | 58,722,218 | ||||
| ASLAN Pharmaceuticals Limited | ||||||||||||||||
| Consolidated Statements of Comprehensive Income1 | ||||||||||||||||
| (in US dollars, unaudited) | ||||||||||||||||
| For the Three Months Ended September 30 |
For the Nine Months Ended September 30 | |||||||||||||||
| 2018 | 2017 |
2018 | 2017 | |||||||||||||
| OPERATING EXPENSES | ||||||||||||||||
| General and administrative | $ | (2,741,101 | ) | $ | (2,238,485 | ) | $ | (8,613,032 | ) | $ | (6,063,944 | ) | ||||
| Research and development | (8,685,051 | ) | (5,636,591 | ) | (22,630,392 | ) | (18,636,725 | ) | ||||||||
| Total operating expenses | (11,426,152 | ) | (7,875,076 | ) | (31,243,424 | ) | (24,700,669 | ) | ||||||||
| LOSS FROM OPERATIONS | (11,426,152 | ) | (7,875,076 | ) | (31,243,424 | ) | (24,700,669 | ) | ||||||||
| NON-OPERATING INCOME AND EXPENSES | ||||||||||||||||
| Interest income | 105,844 | 172,529 | 239,694 | 277,042 | ||||||||||||
| Other income | 187,244 | – | 187,244 | – | ||||||||||||
| Other gains and losses | 40,098 | (160,528 | ) | 170,535 | (627,695 | ) | ||||||||||
| Finance costs | (108,906 | ) | (105,573 | ) | (333,367 | ) | (310,329 | ) | ||||||||
| Total non-operating income and expenses | 224,280 | (93,572 | ) | 264,106 | (660,982 | ) | ||||||||||
| LOSS BEFORE INCOME TAX | (11,201,872 | ) | (7,968,648 | ) | (30,979,318 | ) | (25,361,651 | ) | ||||||||
| INCOME TAX EXPENSE | (4,697 | ) | – | (14,439 | ) | – | ||||||||||
| NET LOSS FOR THE PERIOD | (11,206,569 | ) | (7,968,648 | ) | (30,993,757 | ) | (25,361,651 | ) | ||||||||
| TOTAL COMPREHENSIVE LOSS FOR THE PERIOD | $ | (11,206,569 | ) | $ | (7,968,648 | ) | $ | (30,993,757 | ) | $ | (25,361,651 | ) | ||||
| LOSS PER SHARE | ||||||||||||||||
| Basic | $ | (0.07 | ) | $ | (0.06 | ) | $ | (0.21 | ) | $ | (0.21 | ) | ||||
1 Financial statements in US dollars are prepared by the company
Ends
Media and IR contacts
| Emma Thompson Spurwing Communications Tel: +65 6340 7287 Email: [email protected] |
Robert Uhl Westwicke Partners Tel: +1 858 356 5932 Email: [email protected] |
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Led by a senior management team with extensive experience in global and regional development and commercialisation, ASLAN is headquartered in Singapore and has offices in Taiwan and China. ASLAN’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. ASLAN’s partners include Array BioPharma, Bristol-Myers Squibb, Almirall and CSL. For additional information please visit www.aslanpharma.com.
Forward looking statements
This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the “Company”). These forward-looking statements may include, but are not limited to, statements regarding the Company’s business strategy, the Company’s plans to develop and commercialise its product candidates, the safety and efficacy of the Company’s product candidates, the Company’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for the Company’s product candidates. The Company’s estimates, projections and other forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation the risk factors described in the Company’s US Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company’s prospectus dated May 8, 2018 filed with the US Securities and Exchange Commission on such date.
All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.
